Atlas Trials

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Clinical trial NCT03439085 · TERMINATED

Trial details

NCT number
NCT03439085
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Human Papillomavirus-16 PositiveHuman Papillomavirus-18 PositiveMetastatic Malignant NeoplasmRecurrent Anal Canal CarcinomaRecurrent Cervical CarcinomaRecurrent Malignant NeoplasmRecurrent Penile CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaRefractory Malignant NeoplasmStage IV Anal Cancer AJCC v8Stage IV Cervical Cancer AJCC v8
Start date
2018-11-14
Primary completion
2022-09-20
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.